NCT00250926View on ClinicalTrials.gov

Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

March 31, 2007

Study Completion Date

February 28, 2009

Conditions
Waldenstrom's Macroglobulinemia
Interventions
DRUG

Bortezomib

Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles

DRUG

Dexamethasone

Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles

DRUG

Rituximab

Given intravenously after bortezomib and dexamethasone on day 11 of a 21-day cycle for 8 cycles

Trial Locations (2)

02115

Dana-Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors
All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER